Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.16 USD | -1.15% | -3.63% | -18.33% |
12:33am | US FDA mandates label updates on CAR-T cancer therapies | RE |
Apr. 17 | UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.33% | 82.5B | |
+27.97% | 672B | |
+23.79% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.15% | 211B | |
-0.40% | 203B | |
-10.10% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences Q2 Adjusted EPS Drop While Revenue Gains; Company Boosts 2022 Outlook